<DOC>
	<DOCNO>NCT02536261</DOCNO>
	<brief_summary>The purpose study observe whether dopamine agonist safely withdrawn tumor volume prolactin level invasive prolactinomas involve cavernous sinus effectively control pharmacological treatment .</brief_summary>
	<brief_title>Dopamine Agonists Withdrawal Study Invasive Prolactinomas Involving Cavernous Sinus</brief_title>
	<detailed_description>For giant large invasive prolactinomas involve cavernous sinus , whether drug safely withdrawn tumor volume prolactin ( PRL ) level effectively control pharmacological treatment still remain unknown . The study object patient invasive prolactinomas involve cavernous sinus , invade cavernous sinus extent correspond Grade III IV , accord classification scheme Knosp colleague , undergone pharmacological treatment include bromocriptine cabergoline . Observation start drug withdrawal criterion reach ( PRL remain normal level less two year ; tumor volume shrink 50 % , distance 5mm tumor optical nerve ) , patient randomize withdrawal group continue treatment group.Observational item include change PRL level , tumor volume well vision acuity visual field . If elevate PRL tumor relapse observe , pharmacological treatment restart .</detailed_description>
	<mesh_term>Prolactinoma</mesh_term>
	<mesh_term>Dopamine</mesh_term>
	<mesh_term>Dopamine Agents</mesh_term>
	<mesh_term>Dopamine Agonists</mesh_term>
	<criteria>1 . Aged 15 70 year old , either sex ; 2 . Karnofsky performance status ≥ 70 ; 3 . Patients suffer Invasive prolactinomas involve cavernous sinus , refer ①Serum prolactin level &gt; 200ng/ml , &gt; 4000mIU/L ; ②enhanced Magnetic Resonance image confirm tumor invasion cavernous sinus , i.e . Knosp grade Ⅲ Ⅳ , treat dopamine agonist treatment ; 4 . PRL remain normal level less two year ; 5 . Tumor volume shrink 50 % , distance 5mm tumor optical nerve ; 6 . The patient sign informed consent . 1 . Patients concomitantly take psychotropic drug drug cause elevate PRL ; 2 . Patients parkinson disease take dopaminergic agent ; 3 . Patients prolactinoma receive Gamma knife treatment ; 4 . Patients use dopamine receptor agonist bromocriptine cabergoline ; 5 . Patients take prolactinomas simultaneously ; 6. pregnant lactate woman , woman prepare pregnant ; 7 . Patients poor compliance , implement program strictly .</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Prolactinoma</keyword>
	<keyword>dopamine agonist</keyword>
	<keyword>withdrawal</keyword>
	<keyword>cavernous sinus</keyword>
</DOC>